Plain-English translation of NCT06559436 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called tenecteplase in patients who have had a specific type of stroke caused by a blood clot in smaller-to-medium blood vessels in the brain. The medication works by dissolving the clot and restoring blood flow, and researchers want to learn whether it can help patients even when given many hours after the stroke started. This is important because current treatment options for this type of stroke are still being developed.
Doctors currently have limited proven treatments for this particular type of stroke when mechanical removal of the clot is not available or not possible. This trial aims to see whether this medication can safely improve recovery for these patients, even when given in the extended time window of 4.5 to 24 hours after stroke onset.
You likely qualify if…
You likely don't qualify if…
If you qualify and agree to join, you will be randomly assigned to receive either tenecteplase through an IV or standard medical care. The medication group will receive a single injection of tenecteplase based on body weight (maximum 25 mg). You will be monitored closely with brain imaging and neurological assessments to track how well the medication works and to watch for any side effects. The trial involves 560 patients across multiple hospitals, and your doctors will follow your recovery over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital of University of Science and Technology of China
Enrollment target
~560 participants
Started
October 2024
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wei Hu, MD, PhD
The First Affiliated Hospital of University of Science and Technology of China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.